Esperion Therapeutics reported $14.06M in Interest Expense on Debt for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Abbvie ABBV:US $ 548M 32M
Alnylam Pharmaceuticals ALNY:US $ 42.36M 5.55M
Amgen AMGN:US $ 295M 40M
Biogen BIIB:US $ 66.1M 0.2M
Biomarin Pharmaceutical BMRN:US $ 3.81M 0.04M
Cytokinetics CYTK:US $ 2.75M 1.47M
Eli Lilly And LLY:US $ 84.9M 3.5M
Esperion Therapeutics ESPR:US $ 14.06M 632K
Geron GERN:US 1.48M 344K
Halozyme Therapeutics HALO:US $ 1.76M 0.3M
Intercept Pharmaceuticals ICPT:US $ 6.67M 8.64M
Merk MRK:US $ 243M 34M
Moderna Inc MRNA:US 6M 0
Nektar Therapeutics NKTR:US $ 7.53M 0.6M
Pfizer PFE:US $ 322M 6M
Ptc Therapeutics PTCT:US $ 23.61M 1.01M
Puma Biotechnology PBYI:US $ 2.66M 0.05M
Regeneron Pharmaceuticals REGN:US $ 13.6M 0.5M
Sarepta Therapeutics SRPT:US $ 15.8M 0.25M
United Therapeutics UTHR:US $ 4.7M 0M